SCRI Tissue Testing Registry
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.
| Condition | Intervention |
|---|---|
|
Melanoma Myelodysplastic Syndrome Multiple Myeloma Lymphoma |
Other: Tissue Registry Study |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort |
| Official Title: | SCRI Tissue Testing Registry |
- To establish an electronic registry to store information from patients who have provided their consent allowing use of their tissue sample(s) for future testing. [ Time Frame: 120 months ] [ Designated as safety issue: No ]
- To perform testing on the tissue samples to learn more about specific types of cancer and/or other diseases [ Time Frame: 120 months ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Potential retention of tissue blocks for future study.
| Estimated Enrollment: | 500 |
| Study Start Date: | May 2010 |
| Estimated Study Completion Date: | May 2020 |
| Estimated Primary Completion Date: | May 2020 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
1
The SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date.
|
Other: Tissue Registry Study
If a patient consents to allowing the use of their tumor tissue sample(s) for testing/analysis at a future date, their name and information will be stored electronically in a registry that will be managed by SCRI. SCRI may then use the information contained in this registry (such as disease indication, demographic information, etc.) at any time in the future to select tissue samples on which to perform testing/analyses.
|
Detailed Description:
Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.
This study will consist of a registry of patients who have agreed to allow their tissue sample(s) (even those taken prior to their participation in an SCRI-sponsored trial) to be used by the SCRI Oncology Research Consortium at some point in the future for testing and analysis of expression analysis and/or analysis of tumor markers. The registry will be contained in an electronic database, and will be sorted by disease indication. (Note: Patients will not be asked to return at a future date and have tissue samples collected; rather, SCRI will have the authorization to obtain pre-existing samples).
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
The SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date.
Inclusion Criteria:
- Patients must be >= 18 years of age.
- Patients must be able to provide written informed consent.
Exclusion Criteria:
- Not Applicable
Contacts and Locations| Contact: Howard Burris, M.D. | 615-329-7274 | hburris@tnonc.com |
| Contact: Trials Info | 615-329-7274 | trialsinfo@scresearch.net |
| United States, Tennessee | |
| Tennessee Oncology, PLLC | Recruiting |
| Nashville, Tennessee, United States, 37023 | |
| Study Chair: | Howard Burris, M.D. | Sarah Cannon Research Institute |
More Information
No publications provided
| Responsible Party: | Sarah Cannon Research Institute |
| ClinicalTrials.gov Identifier: | NCT00965861 History of Changes |
| Other Study ID Numbers: | SCRI MISC 39 |
| Study First Received: | August 24, 2009 |
| Last Updated: | January 31, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Sarah Cannon Research Institute:
|
Tissue Registry Tissue Collection Unknown Primary Breast Lung Gastrointestinal Bone Marrow Transplant Chronic Lymphocytic Leukemia Central Nervous System |
Head and Neck Melanoma Myelodysplastic syndrome Multiple Myeloma Lymphoma Gynecologic Genitourinary Refractory Malignancy |
Additional relevant MeSH terms:
|
Lymphoma Melanoma Multiple Myeloma Neoplasms, Plasma Cell Myelodysplastic Syndromes Preleukemia Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Neuroendocrine Tumors |
Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Nevi and Melanomas Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Bone Marrow Diseases Precancerous Conditions |
ClinicalTrials.gov processed this record on June 17, 2013